- Home
- ARVN vs NAPA Comparison
ARVN vs NAPA Comparison
Compare ARVN & NAPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARVN
- NAPA
- Stock Information
- Founded
- ARVN 2015
- NAPA 1976
- Country
- ARVN United States
- NAPA United States
- Employees
- ARVN N/A
- NAPA N/A
- Industry
- ARVN Biotechnology: Pharmaceutical Preparations
- NAPA Beverages (Production/Distribution)
- Sector
- ARVN Health Care
- NAPA Consumer Staples
- Exchange
- ARVN Nasdaq
- NAPA Nasdaq
- Market Cap
- ARVN 1.7B
- NAPA 1.6B
- IPO Year
- ARVN 2018
- NAPA 2021
- Fundamental
- Price
- ARVN $27.04
- NAPA $10.97
- Analyst Decision
- ARVN Strong Buy
- NAPA Buy
- Analyst Count
- ARVN 15
- NAPA 8
- Target Price
- ARVN $57.50
- NAPA $10.76
- AVG Volume (30 Days)
- ARVN 562.1K
- NAPA 4.5M
- Earning Date
- ARVN 11-05-2024
- NAPA 12-04-2024
- Dividend Yield
- ARVN N/A
- NAPA N/A
- EPS Growth
- ARVN N/A
- NAPA N/A
- EPS
- ARVN N/A
- NAPA 0.45
- Revenue
- ARVN $93,300,000.00
- NAPA $405,481,000.00
- Revenue This Year
- ARVN $179.49
- NAPA $21.97
- Revenue Next Year
- ARVN N/A
- NAPA $8.06
- P/E Ratio
- ARVN N/A
- NAPA $24.37
- Revenue Growth
- ARVN N/A
- NAPA 0.62
- 52 Week Low
- ARVN $13.57
- NAPA $5.38
- 52 Week High
- ARVN $53.08
- NAPA $11.08
- Technical
- Relative Strength Index (RSI)
- ARVN 59.76
- NAPA 85.84
- Support Level
- ARVN $25.42
- NAPA $10.92
- Resistance Level
- ARVN $29.24
- NAPA $11.00
- Average True Range (ATR)
- ARVN 1.21
- NAPA 0.09
- MACD
- ARVN 0.29
- NAPA 0.37
- Stochastic Oscillator
- ARVN 58.72
- NAPA 99.47
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
About NAPA The Duckhorn Portfolio Inc.
The Duckhorn Portfolio Inc produces luxury and ultra-luxury wine across a portfolio of winery brands, including Duckhorn Vineyards, Paraduxx, Goldeneye, Migration, Decoy, Canvasback, Calera, Kosta Browne, Greenwing and Postmark. Its revenue is comprised of wholesale and direct-to-consumer sales. Wholesale revenue is generated through sales directly to California retailers and restaurants, sales to distributors and agents located in other states throughout the United States, and sales to export distributors that sell internationally.